NCT07906262Active, not recruiting
Efficacy of Rimegepant 75 mg for the Acute Treatment of Migraine: a Bayesian Individual Participant Data Meta-analysis Standardized to Defined Target Populations
Source: ClinicalTrials.gov · Last updated 30 Oct 2026
Brief summary (registry, in English)
This non-interventional study will evaluate the efficacy of rimegepant 75 mg compared with placebo for the acute treatment of moderate or severe migraine attacks using individual participant data (IPD) from six completed randomized, double-blind, placebo-controlled clinical trials. The analysis includes data from adult participants with migraine with or without aura enrolled across studies conducted in the United States, China, South Korea, Japan, and multiple European and other international locations. Although the efficacy of rimegepant has been established in individual trials and previous pooled analyses, conventional meta-analyses provide average treatment effects based on the mix of participants enrolled in the included studies and may not reflect outcomes expected in specific patient populations. The primary objective is to estimate the average treatment effects of rimegepant 75 mg relative to placebo for moderate or severe migraine attacks with respect to pain and symptom relief in prespecified target populations, including regional populations from Europe, the United States, China, South Korea, and Japan. A secondary objective is to evaluate treatment effects within clinically relevant subgroups defined by demographic and clinical characteristics. Because this study uses existing data from completed clinical trials, no new participant recruitment, treatment assignment, or data collection will be conducted. The findings will contribute to the evidence base for rimegepant in the acute treatment of migraine.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 1 (actual)
- First submitted
- 9 Oct 2026
- Start date
- 12 Oct 2026
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Pfizer
- Diseases
- Migraine
- NCT number
- NCT07906262
What you commit to
- Study type: Observational
- Participants enrolled: 1
- From 12 Oct 2026 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Participants with missing treatment assignment information.
- Participants lacking data necessary for evaluation of the relevant efficacy endpoints or prespecified covariates used in the analyses.
- Participants excluded from the parent clinical trials according to the original study-specific eligibility criteria.
Who the study is looking for
- Participants enrolled in one of six completed randomized, double-blind, placebo-controlled clinical trials of rimegepant 75 mg for the acute treatment of migraine.
- Adults diagnosed with migraine with or without aura according to the eligibility criteria of the parent clinical trial.
- Randomized to receive either rimegepant 75 mg or placebo for treatment of a qualifying moderate or severe migraine attack.
- Availability of participant-level data required for the planned analyses.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pfizer Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.